Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded the novel anticoagulant ...

Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies. The OCEANIC trial ...

Successful drug development is imperative to Bayer amid multiple challenges. The failure of a late-stage study on asundexian was a major setback for the company. BAYRY is also working to expand ...

In the OCEANIC-AF trial, asundexian resulted in a small increase in the rates of stroke and lowered bleeding compared with apixaban in patients with atrial fibrillation (AF) who were naive to oral ...

Bayer reported that ... The failure of a late-stage study on asundexian was a major setback for the company. In the past 30 days, NVO’s EPS estimate for 2025 has increased to $3.93 from $3 ...